Why Did Align Technology (ALGN) Move Today?

Align Technology (ALGN) continues to draw investor attention after recent share price moves, with the stock last closing at $162.55. The company reported annual revenue of $4.14b and net income of $413.58m.

See our latest analysis for Align Technology.

Recent trading has been choppy for Align Technology, with a 1-day share price return of 2.27% following a 7-day share price decline of 10.35%, while the 1-year total shareholder return of 8.68% contrasts with a 3-year total shareholder return that has fallen 54.38%. This suggests momentum is still rebuilding after a difficult few years.

If Align Technology’s recent swings have you thinking about broader opportunities in the sector, it could be a good time to scan for other healthcare AI stocks using the 40 healthcare AI stocks.

The recent pullback leaves Align Technology trading at a sizeable discount to analyst targets and one estimate of fair value. Is the market being sensibly cautious after past volatility, or is it now underpricing the business?

Most Popular Narrative: 22.3% Undervalued

Align Technology’s most followed narrative points to a fair value of $209.07 compared with the last close at $162.55. That gap rests on detailed assumptions about growth, profitability, and the discount rate of 7.45% used to bring future cash flows back to today.

The continued expansion of clinical indications for Invisalign (such as Invisalign First for teens/kids and palate expanders) and the increasing adoption by general practitioner dentists are broadening Align's addressable market, positioning the company for higher long-term revenues and double-digit earnings growth as these new segments mature.

Want to see what sits behind that projected earnings step up? The narrative leans on steady revenue expansion, improving margins, and a future earnings multiple that needs to compress slightly from today’s level.

Result: Fair Value of $209.07 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Align Technology’s story still faces two key risks, including pressure from lower priced clear aligner products and ongoing uncertainty around the EU antitrust investigation.

Find out about the key risks to this Align Technology narrative.

With Align Technology showing both clear risks and potential rewards, it makes sense to look at the full picture now and shape your own view. To weigh up both sides in one place, start with the following: 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Align Technology?

If Align Technology has sharpened your interest, do not stop here. Broaden your watchlist now so you are not reacting after the best ideas have moved.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocks

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Is it a safer bet on gold to have just exposure to ETFs?

Between 2003 and 2011, gold nearly went 5x. Dollar went weak too. The gold companies did bad. It is worth noting that between 2003 and 2011, there was 2008! I will leave it your inference and research.

Provides Invisalign clear aligners, Vivera retainers, and iTero intraoral scanners and services in the United States, Switzerland, and internationally.

Flawless balance sheet and undervalued.